Vident Investment Advisory, LLC Genmab A/S Transaction History

Vident Investment Advisory, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$37.4 - $42.94 $515,072 - $591,369	-13,772 Reduced 63.72%	7,842 $298,000
Q1 2023 May 15, 2023	BUY	$34.88 - $43.22 $34,217 - $42,398	981 Added 4.75%	21,614 $816,000
Q4 2022 Feb 14, 2023	SELL	$33.8 - $47.06 $125,330 - $174,498	-3,708 Reduced 15.23%	20,633 $874,000
Q3 2022 Nov 14, 2022	SELL	$31.52 - $373.61 $38,801 - $459,913	-1,231 Reduced 4.81%	24,341 $726,000
Q2 2022 Aug 15, 2022	SELL	$26.83 - $38.57 $141,179 - $202,955	-5,262 Reduced 17.07%	25,572 $830,000
Q1 2022 May 16, 2022	BUY	$30.95 - $39.68 $165,273 - $211,891	5,340 Added 20.95%	30,834 $1.11 Million
Q4 2021 Feb 14, 2022	SELL	$35.87 - $47.12 $284,162 - $373,284	-7,922 Reduced 23.71%	25,494 $1.01 Million
Q3 2021 Nov 12, 2021	SELL	$41.55 - $48.72 $98,764 - $115,807	-2,377 Reduced 6.64%	33,416 $1.46 Million
Q2 2021 Aug 13, 2021	SELL	$32.88 - $44.57 $205,828 - $279,008	-6,260 Reduced 14.89%	35,793 $1.46 Million
Q4 2020 Feb 08, 2021	BUY	$33.66 - $40.76 $1.42 Million - $1.71 Million	42,053 New	42,053 $1.71 Million

234

52.3M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $12.3B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.